2023 World Conference on Lung Cancer (Posters)-P1.27. Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT)

P1.27. Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT) - PDF(Abstract)

Back to course

Pdf Summary

The abstract provides an overview of a clinical trial titled "Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT)" that is scheduled to be presented at WCLC 2023. The trial aims to explore the efficacy and safety of the third-generation EGFR-TKI aumolertinib as adjuvant therapy in stage I EGFR-mutated NSCLC patients with high-grade patterns.<br /><br />The introduction section explains that high-grade patterns in non-small cell lung cancer (NSCLC) patients, such as solid, micropapillary, or complex gland components, are associated with poorer prognosis. Adjuvant chemotherapy has shown benefit in micropapillary predominant patients even in stage IA. Third-generation EGFR-TKIs have also been found to be effective in postoperative adjuvant therapy in NSCLC patients with EGFR mutations. However, there is currently no prospective study on the use of third-generation EGFR-TKIs in stage I NSCLC patients with high-grade patterns.<br /><br />The methods section describes the design of the study, which is a prospective, multi-center, two-arm trial. Stage I EGFR-mutated NSCLC patients with solid, micropapillary, and/or complex gland components above 10% will be enrolled. After radical lung cancer surgery, the patients will either receive oral aumolertinib as adjuvant therapy or undergo observation. The trial will measure the primary endpoint of 2-year disease-free survival rate, as well as secondary endpoints including 3-, 4-, and 5-year disease-free survival rates, 5-year overall survival rate, safety, and quality of life. Circulating tumor DNA will also be monitored throughout the study.<br /><br />The abstract concludes by stating that recruitment for the study is ongoing, with the first patient enrolled in January 2022. As of April 2023, more than half of the patients have been enrolled. The abstract provides keywords related to the study, including aumolertinib, high-grade patterns, and NSCLC.

Asset Subtitle

Baohui Han

Meta Tag

Speaker Baohui Han

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

clinical trial

Efficacy and Safety

Aumolertinib

adjuvant therapy

Resectable Stage I NSCLC

high-grade patterns

EGFR Mutations

APPOINT

WCLC 2023

third-generation EGFR-TKI